Takeda FY20 Profit Surges, Revenue Drops; Guides For Weak FY21 Profit

  • Takeda Pharmaceutical Co Ltd TAK reported an FY20 net profit of ¥376 billion, a 750% Y/Y increase, reflecting gains on non-core asset sales and lower acquisition-related expenses.
  • Takeda exceeded its $10 billion non-core asset divestiture target and has announced 12 deals since January 2019 to date for a total aggregate value of up to $12.9 billion.
  • Core net income expanded around 9% Y/Y to ¥655.5 billion.
  • Operating profit grew 407.2% Y/Y to ¥509.3 billion, and core operating profit remained unchanged at ¥967.9 billion.
  • Revenue of ¥3.2 trillion fell 2.8% from last year. On an underlying basis, revenue grew 2.2%, driven by the growth of Takeda's 14 global brands, up 16% Y/Y.
  • The company's five key business areas — Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience — with ¥2.6 trillion reported revenue delivered Y/Y underlying revenue growth of 4.7%.
  • At an underlying core operating profit margin of 30.2%, the company is also deleveraging, with a net debt/adjusted EBITDA ratio of 3.2x at the end of Q4, down from 3.8x in March 2020. Takeda is on course to meet its medium-term deleveraging goal of 2x within FY2021-FY2023.
  • Operating cash flow increased by 50.9% to ¥1 trillion. Free cash flow ¥1.2 trillion representing an increase of 27.9% Y/Y.
  • Guidance: For FY21, the company projects a net profit of ¥250 billion, core EPS of ¥394, operating profit of ¥488 billion, and core operating profit of ¥930 billion, all lower than FY20.
  • However, revenue for the year is expected to be ¥3.4 trillion, +5.4% than last year.
  • Takeda expects underlying revenue growth to accelerate to "mid-single-digit." Underlying core operating profit and underlying core EPS are expected to also grow at "mid-single-digit."
  • Tt anticipates up to six regulatory submissions by year-end FY2021, with the potential for four approvals.
  • Price Action: TAK shares closed 0.5% higher at $16.96 on Monday.

Posted In: BriefsBiotechEarningsNewsGuidanceHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.